LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers.

    Vandergaast, Rianna / Carey, Timothy / Reiter, Samantha / Lathrum, Chase / Lech, Patrycja / Gnanadurai, Clement / Haselton, Michelle / Buehler, Jason / Narjari, Riya / Schnebeck, Luke / Roesler, Anne / Sevola, Kara / Suksanpaisan, Lukkana / Bexon, Alice / Naik, Shruthi / Brunton, Bethany / Weaver, Scott C / Rafael, Grace / Tran, Sheryl /
    Baum, Alina / Kyratsous, Christos A / Peng, Kah Whye / Russell, Stephen J

    mSphere

    2021  Volume 6, Issue 3, Page(s) e0017021

    Abstract: ... validated high-throughput assays for measuring titers of SARS-CoV-2-neutralizing antibodies are not ... generally available. Here, we describe the development and validation of IMMUNO-COV v2.0, a scalable ... titers, calculated using a standard curve consisting of stepped concentrations of SARS-CoV-2 spike ...

    Abstract Neutralizing antibodies are key determinants of protection from future infection, yet well-validated high-throughput assays for measuring titers of SARS-CoV-2-neutralizing antibodies are not generally available. Here, we describe the development and validation of IMMUNO-COV v2.0, a scalable surrogate virus assay, which titrates antibodies that block infection of Vero-ACE2 cells by a luciferase-encoding vesicular stomatitis virus displaying SARS-CoV-2 spike glycoproteins (VSV-SARS2-Fluc). Antibody titers, calculated using a standard curve consisting of stepped concentrations of SARS-CoV-2 spike monoclonal antibody, correlated closely (
    MeSH term(s) Animals ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; Chlorocebus aethiops ; High-Throughput Screening Assays/methods ; Humans ; Limit of Detection ; Neutralization Tests/methods ; Severity of Illness Index ; Vero Cells
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral
    Language English
    Publishing date 2021-06-02
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Validation Study
    ISSN 2379-5042
    ISSN (online) 2379-5042
    DOI 10.1128/mSphere.00170-21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: IMMUNO-COV™ v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers

    Vandergaast, Rianna / Carey, Timothy / Reiter, Samantha / Lathrum, Chase / Lech, Patrycja / Gnanadurai, Clement / Haselton, Michelle / Buehler, Jason / Narjari, Riya / Schnebeck, Luke / Roesler, Anne / Sevola, Kara / Suksanpaisan, Lukkana / Bexon, Alice / Naik, Shruthi / Brunton, Bethany / Weaver, Scott C. / Rafael, Grace / Tran, Sheryl /
    Baum, Alina / Kyratsous, Christos A. / Peng, Kah-Whye / Russell, Stephen J.

    medRxiv

    Abstract: ... demonstrate the feasibility and utility of IMMUNO-COV™ v2.0 for measuring SARS-CoV-2-neutralizing ... validated high-throughput assays for measuring titers of SARS-CoV-2-neutralizing antibodies are not ... using a clinical isolate of SARS-CoV-2. IMMUNO-COV™ v2.0 was comprehensively validated using ...

    Abstract Neutralizing antibodies are key determinants of protection from future infection, yet well-validated high-throughput assays for measuring titers of SARS-CoV-2-neutralizing antibodies are not generally available. Here we describe the development and validation of IMMUNO-COV™ v2.0 a scalable surrogate virus assay, which titrates antibodies that block infection of Vero-ACE2 cells by a luciferase-encoding vesicular stomatitis virus displaying SARS-CoV-2 spike glycoproteins (VSV-SARS2-Fluc). Antibody titers, calculated using a standard curve consisting of stepped concentrations of SARS-CoV-2 spike monoclonal antibody, correlated closely (p < 0.0001) with titers obtained from a gold-standard PRNT50% assay performed using a clinical isolate of SARS-CoV-2. IMMUNO-COV™ v2.0 was comprehensively validated using data acquired from 242 assay runs performed over seven days by five analysts, utilizing two separate virus lots, and 176 blood samples. Assay performance was acceptable for clinical use in human serum and plasma based on parameters including linearity, dynamic range, limit of blank and limit of detection, dilutional linearity and parallelism, precision, clinical agreement, matrix equivalence, clinical specificity and sensitivity, and robustness. Sufficient VSV-SARS2-Fluc virus reagent has been banked to test 5 million clinical samples. Notably, a significant drop in IMMUNO-COV™ v2.0 neutralizing antibody titers was observed over a six-month period in people recovered from SARS-CoV-2 infection. Together, our results demonstrate the feasibility and utility of IMMUNO-COV™ v2.0 for measuring SARS-CoV-2-neutralizing antibodies in vaccinated individuals and those recovering from natural infections. Such monitoring can be used to better understand what levels of neutralizing antibodies are required for protection from SARS-CoV-2, and what booster dosing schedules are needed to sustain vaccine-induced immunity.
    Keywords covid19
    Language English
    Publishing date 2021-02-19
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.02.16.21251653
    Database COVID19

    Kategorien

To top